炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！

（来源：医学界）

转自：医学界

从破解耐药到前移应用，埃万妥单抗重塑晚期NSCLC治疗全程格局。

*以下内容仅供医疗卫生专业人士浏览。

参考文献：

[1]Passaro A, Wang J, Wang Y, et al. Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study. Ann Oncol. 2024 Jan;35(1):77-90.

[2]Shih JY, Wang J, Wang Y, et al. Amivantamab plus chemotherapy vs chemotherapy among Asian patients with EGFR-mutant advanced NSCLC after progression on osimertinib: A MARIPOSA-2 subgroup analysis. 2023 ESMO Asia. LBA11.

[3]entzler RD, et al. Amivantamab Plus Chemotherapy vs Chemotherapy in EGFR-mutant Advanced NSCLC After Progression on Osimertinib: A Post-progression Analysis of MARIPOSA-2. ELCC Congress 2024, 3MO.

[4]Califano R, Passaro A, Tan JL, et al. Amivantamab plus chemotherapy vs chemotherapy in EGFR-mutant advanced NSCLC after disease progression on osimertinib: Outcomes by osimertinib resistance mechanisms in MARIPOSA-2. 2025 ASCO. Abstract 8639.

[5]NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Non-Small Cell Lung cancer. Version 3. 2025.

[6]中国临床肿瘤学会（CSCO）非小细胞肺癌诊疗指南（2025年）.

[7]Spira AI, Paz-Ares L, Han JY, et al. Preventing Infusion-Related Reactions With Intravenous Amivantamab-Results From SKIPPirr,a Phase 2 Study:A Brief Report.J Thorac Oncol. Published online January 24,2025.

审批编码：CP-556187

批准分发日期：12/6/2025

有效期：12/6/2026